Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology

Surviving cancer is often not a patient’s most challenging battle

With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment.

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community. The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

KU Cancer Center breaks ground for new complex

The University of Kansas Cancer Center broke ground on the future site of a new complex on May 22 that will bring research and patient care into one area for the first time in KU Cancer Center’s history.

May 30, 2025

Vol.51 No.21

Cancer Policy

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

On May 21, staff members of NCI’s dissolved Office of Communications and Public Liaison and friends gathered at the house of Peter Garrett and Ken Crerar.

May 23, 2025

Vol.51 No.20

Cancer Policy

NCI Cancer Information Highlights bulletin cut due to RIFs

NCI’s Cancer Information Highlights bulletin, a section of NCI’s Weekly Digest Bulletin that informs readers of research updates related to cancer causes, prevention, screening, treatment, and coping, will no longer be published due to restructuring and reductions in force at HHS.

May 23, 2025

Vol.51 No.20

Podcast The Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

May 16, 2025

Vol.51 No.19

By Katie Goldberg

Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology

YOU MAY BE INTERESTED IN

Surviving cancer is often not a patient’s most challenging battle

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

KU Cancer Center breaks ground for new complex

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

NCI Cancer Information Highlights bulletin cut due to RIFs

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Renew today!

Subscriber content

Never miss an issue!

Login

Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology

YOU MAY BE INTERESTED IN

Surviving cancer is often not a patient’s most challenging battle

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

KU Cancer Center breaks ground for new complex

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

NCI Cancer Information Highlights bulletin cut due to RIFs

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”